Patrick Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, shared on X:
“Here’s the Lynch syndrome paper from NCI.
The trial is supported by the Cancer Prevention—Clinical Trials Network (CP-CTNet), a grant-funded network from the National Cancer Institute’s (NCI) Division of Cancer Prevention (DCP) that performs early-phase cancer prevention clinical trials. This trial represents the first cross-network trial performed by all five grant recipients and their affiliated organizations, at a total of 16 study sites.
As stated by the authors:
‘Our trial employs a vaccination strategy that addresses common reasons for vaccine failure by targeting multiple antigens, using a proven adenoviral delivery system, and studying an immune-competent high-risk population without active cancer.'”
Title: Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet)
Authors: Ajay Bansal, Elena Stoffel, Ramona Lim, Peter Stanich, Swati Patel, Carol Burke, Michael Hall, Aparajita Singh, Lisa Boardman, Niloy Samadder, Veroushka Ballestar, Charles Muller, Aaron Scott, Kelly Benante, Yanfei Xu, Jens Eickhoff, Meredith Hyun, Jen Zaborek, Lanni Aquila, Asad Umar, Eva Szabo, Gary Della’Zanna, Ellen Richmond, Lisa Bengtson, Jeffrey Schlom, Renee Donahue, Nicole Toney, Lucas Horn, Claudia Palena, James Gulley, Sohini Samaddar, Dennis Moore, Parth Sharma, Rashna Madan, Karen Hurley, Patrick Soon-Shiong, Elizabeth Gabitzsch, Lennie Sender, Dean Brenner, Scott Schuetze, Zora Djuric, Lisa Barroilhet, Patricia Thompson, Julie Bauman, Seema Khan, Eduardo Vilar
Read the Full Article on Frontiers in Immunology.
Other posts featuring Patrick Soon-Shiong on OncoDaily.